source
- FDA approves Mimrylo, first hepcidin-mimicking drug for polycythemia veraThe U.S. Food and Drug Administration announced approval of Mimrylo (rusfertide) for adult patients with polycythemia vera, a rare blood disorder that causes excess red blood cells. The drug mimic…
- AusperBio secures $120 million Series C to push hepatitis B antisense therapy into Phase 3AusperBio Therapeutics announced it has closed a $120 million Series C financing round aimed at moving its hepatitis B antisense oligonucleotide candidate toward late‑stage trials and eventual mark…